This Program Project Grant application presents a coordinated, interactive group of laboratory projects and a core resource, united by a concern with breast cancer and by the use of mouse models of the human disease. It achieves scientific synergy and an economy of effort by the sharing of existing strains, the collaborative development of new strains (e.g., bi-transgenic mice), the configuration and use of a new core facility for the imaging of mouse tumors, the cooperative discovery and selective use of new methods for the characterization of genotypes and phenotypes, and the design, conduct, and analysis of therapeutic trials in laboratory animals using drugs and other reagents developed within the P01. Because active cancer clinicians are intrinsically involved in these efforts, the knowledge gained In our laboratories will have a direct and substantial impact on clinical thinking, education, and research. Project 1, under Dr. Harold Varmus, examines the determinants of tumor progression in mouse models of human breast cancer and related models of ovarian and islet cell neoplasia. Project 2, under Dr. Joan Massague, concerns the TGF-beta eta signaling pathway. Project 3, under Dr. Neal Rosen, develops the ansamycin antibiotics as therapeutic agents and reagents for the study of cancer biology. Project 4, under Drs. Maria Jasin and Mary Ellen Moynahan, explores the consequences of defective homologous repair incurred through BRCA1 and BRCA2 mutations. Project 5, underDr. Robert Benezra, concerns the Id genes and their relation to neoangiogenesis. An Imaging Core, under Drs. Steven Larson and Juri Tjuvajev, supplies advanced imaging technology to the Projects. Dr. Larry Norton serves as Principal Investigator, Dr. Joan Massague as Co-Principal Investigator, and Dr. Agnes Viale as Coordinator of Molecular Array Technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA094060-03
Application #
6803142
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mohla, Suresh
Project Start
2002-09-01
Project End
2007-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
3
Fiscal Year
2004
Total Cost
$2,250,335
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Er, Ekrem Emrah; Valiente, Manuel; Ganesh, Karuna et al. (2018) Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat Cell Biol 20:966-978
Chen, Chun-Chin; Kass, Elizabeth M; Yen, Wei-Feng et al. (2017) ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci U S A 114:7665-7670
Gao, Hua; Chakraborty, Goutam; Zhang, Zhanguo et al. (2016) Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell 166:47-62
Ebbesen, Saya H; Scaltriti, Maurizio; Bialucha, Carl U et al. (2016) Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A 113:3030-5
Malladi, Srinivas; Macalinao, Danilo G; Jin, Xin et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165:45-60
Rodrik-Outmezguine, Vanessa S; Okaniwa, Masanori; Yao, Zhan et al. (2016) Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534:272-6
Chen, Qing; Boire, Adrienne; Jin, Xin et al. (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533:493-498
Kass, Elizabeth M; Lim, Pei Xin; Helgadottir, Hildur R et al. (2016) Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat Commun 7:13241
She, Qing-Bai; Gruvberger-Saal, Sofia K; Maurer, Matthew et al. (2016) Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer 16:587
Yang, C; Li, Z; Bhatt, T et al. (2016) Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene :

Showing the most recent 10 out of 97 publications